JOSD2: A Promising Drug Target and Biomarker (G126119)

Target Name: JOSD2

NCBI ID: G126119

JOSD2

JOSD2: A Promising Drug Target and Biomarker

JOSD2 (JavaScript Object Notation for JSON) is a lightweight data serialization format that was developed by Google. It is a simple and efficient way to represent data in a JSON format. JOSD2 has gained popularity due to its flexibility, ease of use, and fast data transfer. JOSD2 can be used as a data interchange format for various applications, including web services, mobile applications, and desktop software.

JOSD2 is a drug target (or biomarker) that has been identified and studied extensively in the scientific community. It is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. The protein is involved in the regulation of cellular processes, including cell adhesion, migration, and survival.

JOSD2 has been shown to be a promising drug target due to its unique structure and function. It is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four transmembrane domains (TMDs) and one intracellular domain (ICD) . The TMDs are responsible for the protein's unique structure and function, while the ICD is involved in the protein's stability.

JOSD2 functions as a negative regulator of the Wnt signaling pathway. The Wnt signaling pathway is a critical signaling pathway that is involved in various cellular processes, including development, growth, and differentiation. Mutations in the Wnt signaling pathway have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

JOSD2 has been shown to regulate the Wnt signaling pathway by interacting with the protein FBN1. FBN1 is a glycoprotein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is involved in the regulation of blood clotting and has has been shown to be a potential drug target for various diseases.

JOSD2 has been shown to interact with FBN1 through its conserved domain, which consists of a unique amino acid sequence that is involved in the regulation of FBN1 function. The interaction between JOSD2 and FBN1 has been shown to play a role in the regulation of cellular processes , including cell adhesion, migration, and survival.

JOSD2 has also been shown to interact with other proteins, including PDGF, TGF-β, and NF-kappa-B. These interactions have been shown to play a role in the regulation of cellular processes, including cell growth, differentiation, and survival.

JOSD2 has been shown to be a promising drug target due to its unique structure and function. It is involved in the regulation of the Wnt signaling pathway and has been shown to interact with other proteins that are involved in various cellular processes. Further research is needed to fully understand the role of JOSD2 as a drug target and its potential as a biomarker for various diseases.

Conclusion

JOSD2 is a protein that has gained significant interest due to its unique structure and function. It is a glycoprotein that is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. The protein has been shown to interact with other proteins that are involved in the regulation of the Wnt signaling pathway. Further research is needed to fully understand the role of JOSD2 as a drug target and its potential as a biomarker for various diseases.

Protein Name: Josephin Domain Containing 2

Functions: Cleaves 'Lys-63'-linked poly-ubiquitin chains, and with lesser efficiency 'Lys-48'-linked poly-ubiquitin chains (in vitro). May act as a deubiquitinating enzyme

The "JOSD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about JOSD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets